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Although it is a standard practice in high-income countries, determination of the human immunodeficiency virus (HIV) load
is not recommended in developing countries because of the costs and technical constraints. As more and more countries
establish capacity to provide second-line therapy, and as costs and technological constraints associated with viral load testing
decrease, the question of whether determination of the viral load is necessary deserves attention. Viral load testing could
increase in importance as a guide for clinical decisions on when to switch to second-line treatment and on how to optimize
the duration of the first-line treatment regimen. In addition, the viral load is a particularly useful tool for monitoring
adherence to treatment, performing sentinel surveillance, and diagnosing HIV infection in children aged !18 months. Rather
than considering viral load data to be an unaffordable luxury, efforts should be made to ensure that viral load testing becomes
affordable, simple, and easy to use in resource-limited settings.
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BACKGROUND
Scaling up antiretroviral therapy in re-
source-limited regions requires a simpli-
fied approach [1]. Because of inadequate
laboratory capacity, many programs have
minimized laboratory monitoring [2] in
an effort to accelerate widespread avail-
ability of HIV treatment. In particular, the
measurement of HIV-1 RNA levels (i.e.,
viral loads)—which is done routinely to
monitor HIV-infected patients in high-in-
come countries—was not recommended
for use in resource-limited settings in the
2003 World Health Organization (WHO)
guidelines [3]. Equipment to determine
the viral load is often unavailable or sits
unused. Where available, viral load testing
is prohibitively expensive: a single viral
load test costs $20–$160 (in US dollars).
Because the majority of HIV-infected peo-
ple are still unable to access treatment, and
because funding remains limited, it has
been argued that resources should be ap-
plied to prevention measures and to the
initiation of treatment, rather than to per-
formance of expensive laboratory tests
used to monitor patients who are already
receiving treatment [4].
There are, however, a number of im-
portant reasons to implement viral load
testing in resource-limited settings. Nearly
1.5 million people worldwide are receiving
antiretroviral treatment, and this greatly
increases the need to detect cases in which
first-line treatment has failed. More than
800,000 infants are newly infected with
HIV each year, but infection cannot be
readily diagnosed without viral load test-
ing. As the need for viral load testing in-
creases, technologies to determine the viral
load are becoming simpler, and costs are
decreasing [5]. Given the $8.3 billion an-
nual investment in HIV treatment in re-
source-limited settings [6], the question of
whether high-quality, effective HIV care
can be provided without viral load mon-
itoring needs to be revisited. The focus of
this article is the clinical use of viral load
to manage antiretroviral treatment and to
diagnose HIV infection in infants. Other
uses, such as monitoring the level of drug
resistance in a population and assessing
the quality of a treatment program, are
also outlined.
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USE OF VIRAL LOAD
MEASUREMENTS IN HIGH-
INCOME COUNTRIES
In high-income countries, determination
of the CD4 cell count and viral load is
used to determine whether antiretroviral
treatment is indicated, and viral load data
are used to gauge whether antiretroviral
treatment is successful [7, 8]. When viral
replication is suppressed to low levels, re-
sistance mutations cannot emerge, and a
durable treatment response ensues. Viral
replication in the presence of antiretroviral
treatment favors selection of resistance
mutations and treatment failure. Viral
load assays and drug resistance tests are
used routinely in high-income settings to
guide most treatment decisions.
Viral load measurements are optimally
used to guide treatment when 2 conditions
are met. First, effective plasma drug levels
must be assured. It would be erroneous
to conclude that treatment has failed if the
patient’s adherence is poor or if the reg-
imen has not been taken as prescribed
(adherence is not the only issue; drug
quality, bioavailability, and drug interac-
tions can be detrimental). Second, alter-
native drugs must be available. In the ab-
sence of alternatives to a failing regimen,
the use of resources for viral load testing
is ill advised. In high-income countries,
120 antiretrovirals are now available, pro-
viding options for second-, third-, and
even fourth-line (“salvage”) regimens, and
new molecules, such as third-generation
protease inhibitors, integrase inhibitors,
and CCR5 inhibitors, will further expand
the possibilities for salvage therapy. How-
ever, only a few second-line drugs are
available in resource-limited settings.
Although there is a consensus on the
triggers for initiation of treatment (CD4
cell count, 200–350 cells/mL) and on the
viral load targets during treatment (the vi-
ral load should be “undetectable,” mean-
ing that the HIV RNA level is !50 to 400
copies/mL, depending on the assay’s sen-
sitivity), opinions diverge on the critical
issue of the appropriate response to low-
level viremia in patients who are receiving
treatment [7, 8]. In high-income settings,
some clinicians interpret any sustained,
detectable viremia (viral load, 150 copies/
mL) as treatment failure that necessitates
a switch in the regimen, because some re-
sistance mutations are likely to emerge
even with low-level replication. Others
take a more flexible approach, weighing
clinical and immunologic measures of
treatment success, especially in heavily
treatment-experienced patients whose op-
tions for active antiretrovirals are limited.
Also, for any given viral load, the decrease
in the CD4 cell count is slower in patients
who are infected with drug-resistant HIV
than in those who are infected with wild-
type HIV [9]. In some triple-class–expe-
rienced patients, CD4 cell counts may re-
main stable for months or years, provided
that the viral load does not exceed 10,000
copies/mL [10–12].
POTENTIAL BENEFIT OF VIRAL
LOAD MEASUREMENTS
IN RESOURCE-LIMITED
SETTINGS
Treatment failure. Establishment of a
viral load threshold to guide treatment
switch decisions in resource-limited set-
tings is fraught with challenges. In most
national protocols, the options after a
failed first-line regimen are generally lim-
ited to a single second-line regimen. The
prices of second-line regimen drugs are
currently 10-fold higher than the prices of
first-line regimen drugs [13]. Viral load
and resistance testing are rarely available,
and where they are available, the cost and
complexity of testing (which requires skilled
technicians at a referral laboratory and sam-
ple transfer by cold chain) severely limit the
ability to perform these tests routinely. Thus,
the use of routine viral load monitoring in
support of a developed-world strategy based
on monitoring for maximal viral suppres-
sion has not been implemented in most re-
source-limited settings.
In the absence of routine viral load test-
ing, treatment failure has generally been
defined by clinical criteria and CD4 cell
count, and the revised 2006 WHO guide-
lines suggest a number of possible algo-
rithms [3]. However, changes in CD4 cell
counts are difficult to interpret as a result
of individual variations in the immuno-
logical response to antiretroviral treat-
ment. An algorithm based on clinical his-
tory, hemoglobin level, and CD4 cell count
has recently been proposed, but it has not
been validated in routine clinical care [14].
In fact, no validated definition of immu-
nologic treatment failure based on the
CD4 cell count exists, and there are no
data on the long-term outcome of CD4
cell count–guided treatment changes. A
recent study from Botswana suggests that
the utility of CD4 cell count data to predict
virological failure is limited [15]. Because
clinical failure is an even later develop-
ment, defining treatment failure on clin-
ical grounds alone is equally suboptimal.
In the few settings where viral load test-
ing is available, cost issues have modified
the way it is used to approach treatment
failure. A decreasing CD4 cell count trig-
gers concern about treatment failure, and
the viral load is determined to assess vi-
rological failure only in patients with de-
creasing CD4 cell counts. In principle, a
predetermined threshold of virological
failure would then trigger a switch in
therapy; in practice, decisions are made
on a case-by-case basis. Complicating
this approach, studies in resource-limited
settings have shown frequent discordance
between virological and immunological
responses to antiretroviral treatment, in-
cluding a marked increase in CD4 cell
counts in patients without complete viral
suppression or a decrease in CD4 cell
counts in patients with an undetectable
viral load [16].
Thus, 2 critical questions remain. First,
if viral load test results provide an early
sign of treatment failure and predict clin-
ical outcome, can a single viral load
threshold be used to determine when to
switch from a first-line to a second-line
regimen in resource-limited settings? And,
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if so, can a viral load test be made af-
fordable and practical for this use?
The answer to the first question de-
pends on the biology of virological fail-
ure and the availability of second-line
drugs. The longer that viral replication oc-
curs under ineffective plasma drug lev-
els, the more likely it is that mutations
will accumulate, jeopardizing future treat-
ment options. If programs had 2 sequen-
tial regimens with limited cross-resistance
available, resistance testing would not be
needed for at least for some years after
failure of the first regimen. Currently, fail-
ure of the WHO’s recommended first-line
regimens—2 nucleoside reverse-transcrip-
tase inhibitors plus 1 nonnucleoside re-
verse-transcriptase inhibitor—is associ-
ated with thymidine analogue mutations,
the M184V mutation, and nonnucleoside
reverse-transcriptase inhibitor mutations.
A second-line regimen of 2 new nucleo-
side reverse-transcriptase inhibitors (aba-
cavir, didanosine, and/or tenofovir), com-
bined with a boosted protease inhibitor,
can be expected to retain reasonable ac-
tivity. Nonetheless, data from a cross-sec-
tional study from Malawi of 50 patients
who had been exposed to stavudine, la-
mivudine, and nevirapine and who had
viral loads 11000 copies/mL revealed a
highly predictable mutation pattern with-
out thymidine analogue mutations (al-
though the median duration of follow-up
in this cohort was only 8.3 months) [17].
Greater access to an expanded, low-price,
second-line formulary that has minimal
cross-resistance with the first line, com-
bined with rational use of viral load test-
ing, would be sufficient to minimize drug
resistance and maximize the likelihood of
success for patients whose WHO-recom-
mended first-line regimens fail.
Studies can also address the second
question: is there a single threshold or a
narrow range of viral loads that can be
used as a trigger for treatment switches?
Evidence from the PLATO Collaboration
and other studies suggests that, as long as
the viral load remains !10,000 copies/mL,
CD4 cell counts remain stable and the risk
of clinical progression is low [14–16, 18].
Some national programs have set 5000
copies/mL as a threshold for switching
regimens. Additional virological data from
ongoing clinical trials and observational
cohorts in resource-limited settings, com-
bined with genotype data from samples
from patients with low-level viremia, will
help to evaluate different thresholds and
guide the rational use of viral load testing.
Clearly, however, a qualitative test with a
cutoff value of 10,000 copies/mL would be
of immediate practical use.
The interpretation of low viral load data
using this approach warrants comment. In
high-income countries, the significance of
viral loads of 50–1000 copies/mL contin-
ues to be debated, and the concept known
a “blip”—transient, low-level viremia that
returns spontaneously to an undetect-
able level without apparent clinical con-
sequences—has been introduced [19, 20].
The interpretation of low-level viremia in
resource-limited settings may be even
more challenging because of the high rates
of comorbidities, such as tuberculosis, ma-
laria, and other common infections, that
may induce blips [21, 22]. However, with
an assay that has a cutoff value of 10,000
copies/mL, such blips would appropriately
pass unnoticed. Nonetheless, the nature of
blips in resource-limited settings is a re-
search priority.
Adherence monitoring. In Khayelit-
sha, South Africa, antiretroviral treatment
has been accessible since 2001; by April
2006, 13500 adults had started receiving
therapy [23]. Viral load and CD4 cell
count monitoring are routinely performed
at baseline, at months 3 and 6 after the
commencement of treatment, and every 6
months thereafter. Adherence support in-
cludes preparedness counseling, pillboxes,
support groups, and mandatory disclosure
to at least 1 “treatment buddy.” Viral load
testing is also used to identify patients who
need more-intensive adherence support.
When a patient with a viral load 1400
copies/mL is identified, he or she under-
goes a cycle of adherence checks, pill
counts, and weekly counseling sessions for
4 weeks, after which time the viral load is
reassessed.
After 4 years of follow-up, 70% of pa-
tients continued to received their original
regimens, with 17.9% migrating to a sec-
ond-line regimen. In a sample of 598 pa-
tients, 515 (87%) were found to have an
undetectable viral load at 3 months, and
416 (90%) were found to have an unde-
tectable viral load at 6 months. With re-
gard to the remaining patients with de-
tectable viral loads, the ability of their viral
load to return to an undetectable level cor-
related with the timing of detection of their
virological escape and the subsequent in-
tervention in adherence support provided.
Only 25% of patients who were not reeval-
uated for 7 months were able to achieve
an undetectable viral load, compared with
71% of patients who underwent an adher-
ence intervention and a repeated viral load
assessment within 4 months.
Thus, viral load testing combined
with an adherence intervention may
help patients with poor adherence to
therapy maintain use of their first-
line regimen, preventing unnecessary
switches in treatment. Moreover, in set-
tings with very high patient workload,
viral load testing may allow staff to tri-
age between patients who are eligible for
self-administered antiretroviral treat-
ment and patients who need more reg-
ular visits and support. The data from
Khayelitsha are preliminary, and it
should be noted again that broader im-
plementation of strategies to use viral
load data for early detection of non-
adherence to treatment in resource-poor
settings would require a simple, afford-
able viral load assay. Nonetheless, this
approach is proving useful in a number
of settings where viral load testing is
available, including positive experience
reported from programs in Nigeria (J.
Wenkel, personal communication) Bot-
swana (G. Brisson, personal communi-
cation), and Uganda [24]. Further eval-
uation is warranted.
Diagnosis of HIV infection in infants.
In most resource-limited settings, children
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Table 1. Specifications of existing viral load assays and target specifications for a viral load assay appropriate
for resource-limited settings.
Characteristic Available viral load equipment/kit
Target requirements for
viral load devices designed for
resource-limited settings
Assay characteristic
Sample collection method Venipuncture Fingerstick/heelsticka lancet
Sample volume, mL 200–1000 100–200a
Sample preparation Three-step workflow, open system, ultracentrifu-
gation, separate sample preparation area
Minimal (plasma and whole
blood), closed system
Consumables per result 1 blood collection tube, 1 needle, 1 micropipetter,
6 pipet tips, 1 pipettor, 2–4 pipets, reaction
tubes, reagent tubes, reagent reservoirs
1 lancet, 1 capillary collection
tube, 1 disposable cartridge
Reagent characteristics Refrigerated kits (2C–8C) Reagents embedded on cartridge
and stabilized to 40C
Test cost $14–$100 per result !$8 per result
Instrument characteristics
Power requirements AC mains Rechargeable battery
Characteristics Multiple equipment components Handheld/bench-top, single device
Instrument cost $30,000–$60,000 !$1000
Performance
Technician time 10–60 min !10 min
Time to result 3–8 h !2 h
Analytic/diagnostic range Quantitative: from 50 to 106 copies/mL; all clades Semi-quantitative threshold:
10,000a copies/mL; all clades
Training and skill level Advanced training in molecular biology techniques 1–2 days training, 10th grade
education
NOTE. AC, alternating current.
a For diagnosis in infants.
born to HIV-infected mothers are tested
with an antibody test to determine their
HIV infection status. These tests are only
conclusive after 15–18 months because of
the potential for false-positive results as-
sociated with persisting maternal antibod-
ies. Earlier identification of HIV infection
in exposed infants and referral for anti-
retroviral treatment are essential.
Detection of virus by nucleic acid am-
plification is the preferred method for di-
agnosis. Most experts agree that viral load
testing performed when the child is aged
4–14 weeks is optimal; diagnosis of infec-
tion in breast-fed infants may require ad-
ditional testing. Some programs have es-
tablished routine, early infant HIV testing,
in which at-risk infants are identified dur-
ing regular postnatal follow-up visits (e.g.,
vaccination visits) and are tested as early
as 4–6 weeks of age. DNA PCR is widely
used, largely because it is cheaper than
RNA PCR, although it is slightly less sen-
sitive [25–27]. Dried blood spots have
proven to be useful as samples transported
to a reference laboratory [28], but turn-
around of results may still take several
weeks, during which time many infants
are lost to follow-up.
Trials from Malawi, Kenya, and Uganda
have reported a 40%–50% mortality rate
among HIV-infected infants within the
first 24 months of life [29–31]. On-site,
rapid diagnosis of HIV infection in in-
fants would provide health care workers
and caretakers with results during routine
postnatal visits, allowing early treatment
initiation where needed. It would also al-
low savings for overburdened health ser-
vices by screening out as many as 90%–
95% of exposed but uninfected children,
limiting unnecessary use of trimethoprim-
sulfamethoxazole, and guiding strategies
for infant feeding in at-risk babies. For
diagnosis of HIV infection in infants, as
in monitoring in adults, a simple, quali-
tative viral load test with a detection
threshold of 10,000 copies/mL would be
more than sufficient [28].
Other uses: quality assessment, resis-
tance surveillance, and vaccine efficacy
studies. Viral load testing is also used in
resource-limited settings to assess HIV
treatment program quality, to monitor
drug resistance, and to evaluate candidate
vaccines. As a quality benchmark, the
WHO has proposed that 70% of patients
should achieve virological suppression
(defined as a viral load !400 copies/mL)
at 6 months of antiretroviral treatment
in resource-limited settings [32–37]. A
global network of drug resistance sur-
veillance has also been established [32],
and the US National Institutes of Health
has begun planning for viral load testing
in upcoming phase IIb and phase III vac-
cine trials (M. Schito and P. de Souza,
personal communication). The availabil-
ity of simple, affordable viral load tests
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Figure 1. Prototype dipstick to quantify amplified nucleic acids for simplified viral load measurement in resource-limited settings (courtesy of Magda
Dineva and Helen Lee, Diagnostics Development Unit, Cambridge University, United Kingdom).
would expand the reach of each of these
programs [38, 39].
FUTURE ASSAYS FOR VIRAL
LOAD MEASUREMENT
IN RESOURCE-LIMITED
SETTINGS
Four systems to measure viral load are
now in use in high-income settings: the
Abbott real-time HIV-1 PCR assay, the
Bayer Versant HIV-1 RNA 3.0 (bDNA)
assay, the bioMe´rieux NucliSens HIV-1
QT (NASBA) assay, and the Roche Am-
plicor HIV-1 Monitor 1.5 (RT-PCR) assay,
which can also be run in a real-time for-
mat [40, 41]. Each system requires refrig-
erated reagents, multiple instruments, and
isolation rooms to prevent cross-contam-
ination. Highly skilled laboratory techni-
cians proficient in molecular biology tech-
niques and strong laboratory management
are essential. Generic, low-cost reagents
for real-time assays have been developed
for use in resource-limited settings, with
performance comparable to existing assays
[42], and price reductions have been ne-
gotiated for commercial systems [5]. Al-
though these developments are encour-
aging, because of the complexity of nucleic
acid amplification assays, expansion of vi-
ral load testing capacity has been highly
variable in low-income settings.
Two nonnucleic acid viral load detec-
tion methods have also been developed
[43]. One, the ICD p24Ag assay, measures
circulating HIV p24 protein after immune
complex dissociation; this was originally
developed as a research tool. The second,
the Cavidi ExaVir Load assay, uses a mod-
ified ELISA to measure reverse-transcrip-
tase activity, which correlates with circu-
lating HIV RNA levels. Although these are
less complex than nucleic acid assays, both
require refrigerated reagents, multiple in-
struments, and skilled laboratory techni-
cians; moreover, the Cavidi RT ELISA test
results are available only after 3 days [44].
Investigations of the use of p24 assays in
clinical management in Africa have been
disappointing [44, 45]. Clinical validation
for both systems is incomplete.
Given the limitations of current tests for
use in resource-limited settings, imple-
mentation of expanded viral load testing
has been delayed, even in countries such
as Brazil and South Africa, where labo-
ratory infrastructure is more robust. Thus,
in early 2006, Me´decins Sans Frontie`res
organized an expert consultation among
academic experts and end users in re-
source-limited settings to identify the es-
sential characteristics for a new viral load
assay appropriate for resource-limited set-
tings [46]. A survey was also performed
among potential end users at 32 districts
and local hospitals and clinics involved in
the monitoring and care of ∼18,000 pa-
tients in developing countries [47]. The
critical specifications were established, in-
cluding thresholds for adult monitoring
and infant diagnosis, cost, automation,
power requirements, and the technical de-
mands on users (table 1).
Currently available assays do not yet
meet these specifications. Several biotech-
nology developers are attempting to de-
sign new assays along these lines. As one
example, scientists at Cambridge Univer-
sity have recently developed a new ap-
proach to quantify amplified nucleic acid
using a simple dipstick [48] and a signal
amplification system for visual detection
at lower thresholds (figure 1). Other ap-
proaches to viral detection that can meet
the specifications required of a viral load
assay appropriate for resource-limited set-
tings are also in development [49].
CONCLUSIONS
The revised WHO guidelines for HIV
treatment in resource-limited settings re-
leased at the XVI World AIDS Conference
in Toronto in August 2006 [3] specifically
recognize the increasing use of viral load
tests in many countries. For the first time,
viral load data are considered in the cri-
teria to define treatment failure, and viral
load thresholds for resource-limited set-
tings are suggested. These guidelines offer
useful guidance for further research on
this question. Although current assays re-
main expensive, viral load testing may
prevent unnecessary switches to expen-
sive second-line therapies, and the costs
of not monitoring viral loads need to be
considered.
The current practice in resource-limited
settings of basing treatment decisions on
CD4 cell counts and clinical signs can only
lead to potentially dangerous delays and
uncertain outcomes for a number of pa-
tients and widespread transmission of
drug-resistant virus—in particular, in ba-
bies born to mothers with partial treat-
HIV/AIDS • CID 2007:44 (1 January) • 133
ment failure. With the increasing need for
availability of second-line regimens, there
is now a reasonable argument in support
of the widespread, rational use of viral load
testing. Although relatively expensive at
present, it has the potential to prevent un-
necessary switches to expensive second-
line therapies, to assist adherence inter-
vention programs, and to diagnose HIV
infection in infants. We anticipate that ad-
vances in diagnostic technologies will lead
to new viral load assays that will meet the
specifications appropriate for resource-
limited settings.
The focus in resource-limited settings
has been almost exclusively on increasing
access to drugs. Attention must now also
be paid to monitoring to limit the costs
associated with widespread use of expen-
sive second-line therapy and to provide
optimal treatment to patients.
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